Age >/=18 years at screening
Patients with relapsing forms of multiple sclerosis (RMS) with active disease defined by clinical or imaging features: (i) at least one clinical relapse over a 6-month period prior to screening; (ii) AND/OR at least one T1 gadolinium-enhancing lesion or new and/or enlarging T2 lesion as detected by brain Magnetic Resonance Imaging (MRI) performed over a 3 months period prior to screening with no change of Disease-Modifying Treatment(s) (DMT) compared to a previous MRI performed within 24 months before screening
For women of childbearing potential: agreement to use an acceptable birth control method during the treatment period and for at least 12 months after the last dose of ocrelizumab
Participants should be beneficiary of healthcare coverage under the social security system

NCT03589105_inc_T1
Person
Age
NCT03589105_inc_T2
Value
>/=18 years
NCT03589105_inc_T3
Temporal
at screening
NCT03589105_inc_T4
Qualifier
relapsing forms
NCT03589105_inc_T5
Condition
multiple sclerosis (RMS)
NCT03589105_inc_T6
Qualifier
active disease
NCT03589105_inc_T7
Observation
imaging features
NCT03589105_inc_T8
Observation
linical eatures:
NCT03589105_inc_T9
Scope
clinical or imaging features
NCT03589105_inc_T10
Multiplier
t least one ver a 6-month period
NCT03589105_inc_T11
Condition
clinical relapse
NCT03589105_inc_T12
Temporal
prior to screening
NCT03589105_inc_T13
Multiplier
t least one ver a 3 months period
NCT03589105_inc_T14
Temporal
prior to screening
NCT03589105_inc_T15
Condition
T1 gadolinium-enhancing lesion
NCT03589105_inc_T16
Condition
T2 lesion
NCT03589105_inc_T17
Procedure
brain Magnetic Resonance Imaging (MRI)
NCT03589105_inc_T18
Qualifier
enlarging
NCT03589105_inc_T19
Temporal
new
NCT03589105_inc_T20
Scope
new and/or enlarging
NCT03589105_inc_T21
Scope
T1 gadolinium-enhancing lesion or new and/or enlarging T2 lesion as detected by brain Magnetic Resonance Imaging (MRI)
NCT03589105_inc_T22
Scope
T1 gadolinium-enhancing lesion or new and/or enlarging T2 lesion
NCT03589105_inc_T23
Negation
no
NCT03589105_inc_T24
Multiplier
change of
NCT03589105_inc_T25
Procedure
Disease-Modifying Treatment(s) (DMT)
NCT03589105_inc_T27
Scope
at least one clinical relapse over a 6-month period prior to screening; (ii) AND/OR at least one T1 gadolinium-enhancing lesion or new and/or enlarging T2 lesion as detected by brain Magnetic Resonance Imaging (MRI) performed over a 3 months period prior to screening with no change of Disease-Modifying Treatment(s) (DMT) compared to a previous MRI performed within 24 months before screening
NCT03589105_inc_T29
Observation
beneficiary of healthcare coverage